InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS
The European Commission (EC) has granted marketing authorisation under exceptional circumstances for InflaRx’s Gohibic (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS). Patients with ARDS due to Covid-19 who …